Li H, Zhang H, Zhang H, Wang Y, Wang X, Hou H. Survival of gastric cancer in China from 2000 to 2022: a nationwide systematic review of hospital-based studies. J Glob Health. 2022;12:11014. https://doi.org/10.7189/jogh.12.11014.

Article  PubMed  PubMed Central  Google Scholar 

Guo J, Liu C, Pan J, Yang J. Relationship between diabetes and risk of gastric cancer: a systematic review and meta-analysis of cohort studies. Diabetes Res Clin Pract. 2022;187:109866. https://doi.org/10.1016/j.diabres.2022.109866.

Article  CAS  PubMed  Google Scholar 

Ang TL, Fock KM. Clinical epidemiology of gastric cancer. Singapore Med J. 2014;55(12):621–8. https://doi.org/10.11622/smedj.2014174.

Article  PubMed  PubMed Central  Google Scholar 

Wong BC, Lam SK, Ching CK, Hu WH, Kwok E, Ho J, et al. Differential Helicobacter pylori infection rates in two contrasting gastric cancer risk regions of South China. China Gastric Cancer Study Group. J Gastroenterol Hepatol. 1999;14(2):120–5. https://doi.org/10.1046/j.1440-1746.1999.01823.x.

Article  CAS  PubMed  Google Scholar 

Komar OM, Kizlova NM, Trylevych OD, Kravchenko VV. Risk factors for adverse course of gastric and duodenal peptic ulcer. Wiad Lek. 2018;71(1 pt 2):160–4.

PubMed  Google Scholar 

AbdelAziz EY, Tadros MG, Menze ET. The effect of metformin on indomethacin-induced gastric ulcer: involvement of nitric oxide/Rho kinase pathway. Eur J Pharmacol. 2021;892:173812. https://doi.org/10.1016/j.ejphar.2020.173812.

Article  CAS  PubMed  Google Scholar 

Cheung KS, Chan EW, Wong AYS, Chen L, Seto WK, Wong ICK, et al. Metformin use and gastric cancer risk in diabetic patients after Helicobacter pylori eradication. JNCI J Natl Cancer Inst. 2018;111(5):484–9. https://doi.org/10.1093/jnci/djy144.

Article  CAS  Google Scholar 

Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017;60(10):1862–72. https://doi.org/10.1007/s00125-017-4370-8.

Article  CAS  PubMed  Google Scholar 

Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci USA. 2015;112(30):E4111–9. https://doi.org/10.1073/pnas.1511698112.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yaribeygi H, Sathyapalan T, Maleki M, Jamialahmadi T, Sahebkar A. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review. Life Sci. 2020;240:117090. https://doi.org/10.1016/j.lfs.2019.117090.

Article  CAS  PubMed  Google Scholar 

Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121–6. https://doi.org/10.4103/aam.aam_56_18.

Article  PubMed  PubMed Central  Google Scholar 

Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis K, et al. The impact of SGLT2 inhibitors on inflammation: a systematic review and meta-analysis of studies in rodents. Int Immunopharmacol. 2022;111:109080. https://doi.org/10.1016/j.intimp.2022.109080.

Article  CAS  PubMed  Google Scholar 

Zuo B, Li T, Liu X, Wang S, Cheng J, Liu X, et al. Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer. Clin Transl Oncol. 2023;25(11):3188–202. https://doi.org/10.1007/s12094-023-03187-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fareed A, Hussain A. The expanding role of GLP-1: from diabetes management to cancer treatment. Clin Med Insights Endocrinol Diabetes. 2023;16:11795514231213566. https://doi.org/10.1177/11795514231213566.

Article  PubMed  PubMed Central  Google Scholar 

H.K. H. Hospital authority statistical report 2016–2017. 2016–2017.

Authority H: Introduction. https://www.ha.org.hk/visitor/ha_visitor_index.asp?Parent_ID=10004&Content_ID=10008&Ver=HTML (2024). Accessed.

Wu D, Nam R, Leung KSK, Waraich H, Purnomo A, Chou OHI, et al. Population-based clinical studies using routinely collected data in Hong Kong, China: a systematic review of trends and established local practices. Cardiovasc Innov Appl. 2023.

Chou OHI, Zhou J, Lee TTL, Kot T, Lee S, Wai AKC, et al. Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study. Clin Res Cardiol. 2022. https://doi.org/10.1007/s00392-022-02007-0.

Article  PubMed  PubMed Central  Google Scholar 

Lee S, Zhou J, Leung KSK, Wai AKC, Jeevaratnam K, King E, et al. Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. Cardiovasc Drugs Ther. 2023;37(3):561–9. https://doi.org/10.1007/s10557-022-07319-x.

Article  CAS  PubMed  Google Scholar 

Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67(1):28–35. https://doi.org/10.1136/gutjnl-2017-314605.

Article  CAS  PubMed  Google Scholar 

Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 1(1):62–9. https://doi.org/10.2337/dc10-S062.

Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91(1):8–35. https://doi.org/10.1159/000521288.

Article  PubMed  Google Scholar 

Soliman AR, Fathy A, Khashab S, Shaheen N. Comparison of abbreviated modification of diet in renal disease formula (aMDRD) and the Cockroft-Gault adjusted for body surface (aCG) equations in stable renal transplant patients and living kidney donors. Ren Fail. 2013;35(1):94–7. https://doi.org/10.3109/0886022x.2012.731970.

Article  PubMed  Google Scholar 

Wu M-Z, Chandramouli C, Wong P-F, Chan Y-H, Li H-L, Yu S-Y, et al. Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors. Diabetes Metab. 2022;48(6):101367. https://doi.org/10.1016/j.diabet.2022.101367.

Article  CAS  PubMed  Google Scholar 

Pasternak B, Ueda P, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, et al. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. bmj. 2019;366.

Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399–424. https://doi.org/10.1080/00273171.2011.568786.

Article  Google Scholar 

Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–79. https://doi.org/10.1002/sim.6607.

Article  PubMed  PubMed Central  Google Scholar 

Avagyan V, Vansteelandt S. Stable inverse probability weighting estimation for longitudinal studies. Scand J Stat. 2021;48(3):1046–67. https://doi.org/10.1111/sjos.12542.

Article  Google Scholar 

Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: a population-based modelling study. EClinicalMedicine. 2022;47:101404.

Article  PubMed  PubMed Central  Google Scholar 

D’Andrea E, Wexler DJ, Kim SC, Paik JM, Alt E, Patorno E. Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline hba1c levels. JAMA Intern Med. 2023;183(3):242–54.

Article  PubMed  PubMed Central  Google Scholar 

Zhou XL, Xue WH, Ding XF, Li LF, Dou MM, Zhang WJ, et al. Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus: a meta-analysis of cohort studies. Oncotarget. 2017;8(33):55622–31. https://doi.org/10.18632/oncotarget.16973.

Article  PubMed  PubMed Central  Google Scholar 

Xu D, Chandler O, Wee C, Ho C, Affandi JS, Yang D, et al. Sodium-glucose cotransporter-2 inhibitor (SGLT2i) as a primary preventative agent in the healthy individual: a need of a future randomised clinical trial? Front Med (Lausanne). 2021. https://doi.org/10.3389/fmed.2021.712671.

Article  PubMed